An engaging discussion at last night’s Biomed Entrepreneurship class! We were grateful to have Michal Gilon-Yanai from Two Lanterns Venture Partners & Joseph Ferino from @BrownRudnickLLP who shared their knowledge/ perspectives on startup teams & the legal essentials of startups

📢Norovirus Link to Crohn’s Disease May Point to New Therapies. nyulangone.org/news/noroviru… TOV is excited to help facilitate the commercialization of this innovative, early-stage therapeutic for the treatment of #CrohnsDisease from the @cadwellLab and Dr. Shohei Koide’s group.

.@nyulangone's @KathrynMooreLab developed a novel approach to suppress proinflammatory signals for the treatment of chronic inflammatory diseases! They ID'd the immune-augmenting role of the long noncoding RNA CHROMR and developed antisense oligonucleotides to block its function.

The TOV team is at the #RESI conference in #Boston showcasing @nyuniversity's exciting portfolio of technologies and startups to #lifescience investors! If you are attending and would like to connect, please reach out.

Great turnout for the first class in our fall course: Introduction to Biomedical Entrepreneurship - Foundations of Biomedical Startups! med.nyu.edu/research/technol…

Just announced! @nyulangone startup Canaery secured over $4M in seed funding to speed up development of its scent sensing platform. Langone Health participated in the funding round as an investor, making Canaery the 3rd investment from our new venture fund businesswire.com/news/home/2…

What if you could apply sunscreen once in the morning and remain protected from the sun the entire day?@nyuniversity Chemistry Professor Marcus Weck and his lab are working to make that a reality. nyu.edu/about/news-publicati…

📢@nyulangone innovators - A reminder that Therapeutics Alliances, NYU Langone's internal drug development accelerator, is currently seeking proposals for target discovery, target validation, and assay development projects. Application deadline is June 27 med.nyu.edu/research/technol…

TOV is excited to be a part of the 2022 @BIOConvention this week in San Diego. We look forward to connecting with industry while representing some of @nyulangone’s and @nyuniversity’s impactful early-stage research. #therapeutics #drugdiscovery #biotech #techtransfer #BIO2022

The Trabolsi Lab at @NYUAbuDhabi has developed novel organic #nanoparticles for oral #insulin delivery that could revolutionize #diabetes care! These nanoparticles can release insulin in a glucose-responsive manner to lower blood sugar levels. pubmed.ncbi.nlm.nih.gov/3399…

A research team led by Dr. Ann Marie Schmidt at @NYULangone developed a new way to treat #diabetes-associated diseases w/ a #SmallMolecule inhibitor that blocks the RAGE protein's ability to pass on inflammatory signals that injure the heart and kidneys. nyulangone.org/news/experime…

Partnership opportunity! @nyulangone's @paganolab has ID'd new small molecule inhibitors of a key enzymatic complex in #coronaviruses to combat #SARSCoV2. The compounds, when combined w/ known drugs, show therapeutic potential as pan-coronavirus antivirals pubmed.ncbi.nlm.nih.gov/3486…

Partnership opportunity! @nyulangone researchers have developed new antibodies against cancer target CD99 for the treatment of #leukemia & other blood malignancies -featuring nanomolar target affinity, high target selectivity, low toxicity, & IgG framework pubmed.ncbi.nlm.nih.gov/3495…

New patent alert! Dr. Marcus Weck of @nyuniversity’s Chemistry dept has developed new derivatives of a common #sunscreen photofilter, to maximize UV-A protection and better prevent against #skincancer & aging. patents.google.com/patent/US… #skinaging #uvdamage #sunscreen #dendrimers